Literature DB >> 22595961

Rescue of misrouted GnRHR mutants reveals its constitutive activity.

Jo Ann Janovick1, Irina D Pogozheva, Henry I Mosberg, Anda Cornea, P Michael Conn.   

Abstract

G protein-coupled receptors (GPCR) play central roles in almost all physiological functions, and mutations in GPCR are responsible for over 30 hereditary diseases associated with loss or gain of receptor function. Gain of function mutants are frequently described as having constitutive activity (CA), that is, they activate effectors in the absence of agonist occupancy. Although many GPCR have mutants with CA, the GnRH receptor (GnRHR) was not, until 2010, associated with any CA mutants. The explanation for the failure to observe CA appears to be that the quality control system of the cell recognizes CA mutants of GnRHR as misfolded and retains them in the endoplasmic reticulum. In the present study, we identified several human (h)GnRHR mutants with substitutions in transmembrane helix 6 (F(272)K, F(272)Q, Y(284)F, C(279)A, and C(279)S) that demonstrate varying levels of CA after being rescued by pharmacoperones from different chemical classes and/or deletion of residue K(191), a modification that increases trafficking to the plasma membrane. The movement of the mutants from the endoplasmic reticulum (unrescued) to the plasma membrane (after rescue) is supported by confocal microscopy. Judging from the receptor-stimulated inositol phosphate production, mutants F(272)K and F(272)Q, after rescue, display the largest level of CA, an amount that is comparable with agonist-stimulated activation. Because mutations in other GPCR are, like the hGnRHR, scrutinized by the quality control system, this general approach may reveal CA in receptor mutants from other systems. A computer model of the hGnRHR and these mutants was used to evaluate the conformation associated with CA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22595961      PMCID: PMC3385788          DOI: 10.1210/me.2012-1089

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  55 in total

1.  Structural origins of constitutive activation in rhodopsin: Role of the K296/E113 salt bridge.

Authors:  Jong-Myoung Kim; Christian Altenbach; Masahiro Kono; Daniel D Oprian; Wayne L Hubbell; H Gobind Khorana
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

2.  RTP family members induce functional expression of mammalian odorant receptors.

Authors:  Harumi Saito; Momoka Kubota; Richard W Roberts; Qiuyi Chi; Hiroaki Matsunami
Journal:  Cell       Date:  2004-11-24       Impact factor: 41.582

3.  Heterodimerization with beta2-adrenergic receptors promotes surface expression and functional activity of alpha1D-adrenergic receptors.

Authors:  Michelle A Uberti; Chris Hague; Heide Oller; Kenneth P Minneman; Randy A Hall
Journal:  J Pharmacol Exp Ther       Date:  2004-12-22       Impact factor: 4.030

4.  Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins.

Authors:  T Costa; A Herz
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

5.  Use of lithium ion in measurement of stimulated pituitary inositol phospholipid turnover.

Authors:  W R Huckle; P M Conn
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

6.  In vitro coexpression and pharmacological rescue of mutant gonadotropin-releasing hormone receptors causing hypogonadotropic hypogonadism in humans expressing compound heterozygous alleles.

Authors:  Alfredo Leaños-Miranda; Alfredo Ulloa-Aguirre; Jo Ann Janovick; P Michael Conn
Journal:  J Clin Endocrinol Metab       Date:  2005-02-22       Impact factor: 5.958

7.  Addition of a signal peptide sequence to the alpha1D-adrenoceptor gene increases the density of receptors, as determined by [3H]-prazosin binding in the membranes.

Authors:  Ramona Petrovska; Ivo Kapa; Janis Klovins; Helgi B Schiöth; Staffan Uhlén
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

8.  Visualization of unoccupied and occupied gonadotropin-releasing hormone receptors in living cells.

Authors:  X Lin; A Cornea; J A Janovick; P M Conn
Journal:  Mol Cell Endocrinol       Date:  1998-11-25       Impact factor: 4.102

9.  A locus of the gonadotropin-releasing hormone receptor that differentiates agonist and antagonist binding sites.

Authors:  W Zhou; V Rodic; S Kitanovic; C A Flanagan; L Chi; H Weinstein; S Maayani; R P Millar; S C Sealfon
Journal:  J Biol Chem       Date:  1995-08-11       Impact factor: 5.157

10.  Identification of N-glycosylation sites in the gonadotropin-releasing hormone receptor: role in receptor expression but not ligand binding.

Authors:  J S Davidson; C A Flanagan; W Zhou; I I Becker; R Elario; W Emeran; S C Sealfon; R P Millar
Journal:  Mol Cell Endocrinol       Date:  1995-02       Impact factor: 4.102

View more
  4 in total

Review 1.  Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens.

Authors:  P Michael Conn; David C Smithson; Peter S Hodder; M David Stewart; Richard R Behringer; Emery Smith; Alfredo Ulloa-Aguirre; Jo Ann Janovick
Journal:  Pharmacol Res       Date:  2013-12-25       Impact factor: 7.658

2.  Rescue of mutant gonadotropin-releasing hormone receptor function independent of cognate receptor activity.

Authors:  Emery Smith; Jo Ann Janovick; Thomas D Bannister; Justin Shumate; Vadivel Ganapathy; Louis Scampavia; Timothy P Spicer
Journal:  Sci Rep       Date:  2020-06-29       Impact factor: 4.379

3.  Functional relevance of naturally occurring mutations in adhesion G protein-coupled receptor ADGRD1 (GPR133).

Authors:  Liane Fischer; Caroline Wilde; Torsten Schöneberg; Ines Liebscher
Journal:  BMC Genomics       Date:  2016-08-11       Impact factor: 3.969

4.  Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias.

Authors:  Jo Ann Janovick; Timothy P Spicer; Thomas D Bannister; Louis Scampavia; P Michael Conn
Journal:  PLoS One       Date:  2017-08-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.